Sanofi eyes late-stage and commercial acquisitions to counter upcoming Dupixent revenue drop

Sanofi said on its third‑quarter earnings call that it is looking to acquire late‑stage and commercial medicines to sustain growth after Dupixent loses exclusivity.

CEO Belén Garijo highlighted the company’s strong cash‑flow generation as the basis for funding business‑development and M&A activity, emphasizing assets that can be derisked scientifically and clinically while leveraging Sanofi’s commercial strengths.

CFO François Roger added that a solid balance sheet and low leverage give Sanofi access to external financing for the next set of growth drivers.

The French drugmaker reported a beat‑and‑raise quarter, with Dupixent and its vaccine franchise exceeding expectations, underscoring the urgency to diversify its pipeline.